InVivium Capital
Venture capitalChicago · Seed–Growth · 6 people tracked
Also known as INVIVIUM CAPITAL MANAGEMENT, LLC
Find your way into InVivium Capital
Sign up to see every warm intro you have to InVivium Capital
- Paths you didn't know you had: your email and LinkedIn already hold routes to the InVivium Capital team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
InVivium Capital invests in transformative life sciences and healthcare innovation. The firm believes the healthcare industry is undergoing dramatic change that creates significant opportunity for groundbreaking innovation to meaningfully improve lives, health, and the quality of care people receive. Its stated mission is to work closely alongside exceptional founders and teams to bring transformational technologies to life.
Source: firm website, verified Sep 29, 2026.
Team · 6 people
from the firm's websiteWhat they invest in
from 7 of 9 portfolio companiesBiotech ×6Healthtech ×4AI & Machine Learning ×1Deep Tech ×1Digital Health ×1Medical Devices ×1Mental Health ×1Robotics ×1
HQs:United States×6
Investments · 9 tracked
founders shown can be your intro pathBy year:2024 · 12023 · 12021 · 12020 · 14 dated
Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates.
BiotechDigital HealthMental HealthMountain View, US
Amit Etkin(Founder)inAdam Savitz(Executive Officer)inMichael Hanley(Executive Officer)Nicholas Smith(Chief Financial Officer and Chief Business Officer)inAaron Weaver(Director)Po Yu (Jeff) Chen(Director)
Board seatMichael Liang· per SEC Form D
Co-investorsAble PartnersAlpha Wave GlobalK2 HealthVenturesKorify CapitalMana VenturesNat Turner+11 more
Avalyn Pharma develops inhaled therapies for pulmonary fibrosis, using a nebulization approach that delivers treatment directly to the lungs to reduce the tolerability problems of existing oral therapies.
BiotechHealthtech
Lyn Baranowski(CEO)in
Co-investorsAndera PartnersCatalio Capital Management, LPF-Prime CapitalNorwest Venture PartnersPivotal Life SciencesRiverVest Venture Partners+9 more
Grove Biopharma develops Bionic Biologics, a drug discovery platform combining AI-enabled molecular design, precision polymer chemistry, and experimental biology to target protein-protein interactions that are inaccessible to conventional therapeutics.
AI & Machine LearningBiotechDeep TechChicago, US
Geoffrey Duyk(CEO)in
Co-investorsDCVC (Data Collective)DCVC BioPortal InnovationsDeepWork Capital
Hinge Bio is a biotechnology company developing next-generation therapeutics based on its GEM-DIMER platform, aimed at improving efficacy and reducing resistance and side effects.
BiotechHealthtechBurlingame, US
Daniel J. Capon(Director)Carin Mueller Rollins(Co-Founder & Chief Operating Officer)Harold E. Selick, PhD(Executive Officer, Director)Miriam Siekevitz(Executive Officer)inHarold E. "Barry" Selick(Chief Executive Officer & Director)Paul Brunetta(Chief Medical Officer)in
Co-investorsPoint72Agent CapitalBaruch Future VenturesRidgeback Capital
Onchilles Pharma is a biopharmaceutical company developing novel therapeutics based on scientific research to address unmet medical needs.
BiotechSan Diego, US
Lev Becker, Ph.D.(Director)Marc Nasoff(Chief Development Officer)Court Turner(Executive Officer, Director)Kevin Li, Ph.D.(Director)
Virtual Incision develops a miniaturized robotic-assisted surgery (miniRAS) system called MIRA, designed to fit within hospitals' existing infrastructure.
BiotechHealthtechMedical DevicesRoboticsLincoln, US
Dmitry Oleynikov(Director)Shane Farritor(Executive Officer, Director)John P. Murphy(Executive Officer, Director)inMukund Srinivasan(Executive Officer)inJames M. Alecxih(Executive Officer, Director)Robert Larid(Executive Officer)
Co-investorsArboretum VenturesBaird CapitalEndeavour VisionInvest NebraskaPrairieGold Venture Partners
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
CALA HEALTH, INC.555 Bryant StreetRevelyx Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 2
2 IPOsAlto NeuroscienceNYSE: ANROAvalyn Pharma IncNASDAQ: AVLN
Portfolio news
latest coverage across their companiesOnchilles Pharma · onchillespharma.com · Nov 7, 2025
Frequently asked questions
- How many investments has InVivium Capital made?
- InVivium Capital has 9 tracked investments, 2 of which have exited, including 1 dated in the last 24 months.
- What stage does InVivium Capital invest at?
- InVivium Capital invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does InVivium Capital focus on?
- InVivium Capital focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
- Where is InVivium Capital located?
- InVivium Capital is headquartered in Chicago, US.
- Who does InVivium Capital co-invest with?
- InVivium Capital most often shares deals with DCVC (Data Collective), Norwest Venture Partners, Revolution, among 32 tracked co-investors.
Similar investors
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
Khosla Ventures is a venture capital firm that backs bold, early-stage, technology-driven companies across deep tech and other sectors, providing hands-on 'venture assistance' to help founders build category-defining businesses.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Lumira Ventures is a North American life sciences venture capital firm that partners with mission-driven entrepreneurs to build companies developing and commercializing healthcare products for patients.
OrbiMed is a healthcare-focused investment firm providing tailored financing solutions and global resources to build world-class healthcare companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

































